UNSPSC 51384202: Loxoprofen

This classification denotes a cyclooxygenase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3583H0GZAP. European Medicines Agency schedules Loxoprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08609MIG. Loxoprofen generally arises in the molecular formula C15H18O3.

UNSPSC 51384202 Loxoprofen is a Commodity code that in practice covers pharmaceutical products and related drug-delivery systems procured by state and local health agencies. Recent state and local opportunities under this code show demand for naloxone and drug deactivation systems, generic multi-source pharmaceuticals distributed through authorized wholesalers to state and local facilities, and direct-to-manufacturer prescription programs designed to improve fulfillment efficiency and cost management. Issuing bodies include county health departments, state health and human services commissions, and multi-state cooperative purchasing alliances that aggregate demand across participating jurisdictions. Vendors must typically comply with cGMP and Drug Supply Chain Security Act requirements, maintain relationships with authorized wholesalers, and hold appropriate insurance coverages including commercial general liability and professional liability.

Activity is concentrated in Florida and Texas, with multi-state cooperative purchasing centered in Minnesota. Representative recent opportunities include Seminole County, Florida's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (IFB60459723LAS, due July 26, 2023) requiring quarterly deliveries to the Seminole County Community Health Building in Sanford with a two-year initial term and one-year renewal option; the Texas Health and Human Services Commission's Request for Information on a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program (HHS0017013, posted April 3, 2026) to explore direct relationships between the state pharmacy benefit program and manufacturers outside traditional pharmacy benefit manager arrangements; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products (S1070000015802, due March 26, 2026) serving participating state and local facilities across multiple states, with awarded vendors effective July 1, 2026 and a two-year initial term. Vendors must submit pricing in designated electronic formats, comply with FDA requirements, and agree to administrative fees and performance penalty structures.